Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating the efficacy of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy by Merck, combined with LENVIMA (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor […]